Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:53:40.388Z.
Calculation as of: 2026-10-06T19:53:40.388Z.
Quote observation: 2026-10-06T19:50:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 833b8a33f5e3aa548e06775940c7a83493d9a3083fc648ecb3f8ecd80d633b38
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$236.17M
EBITDA Yield
N/A
TTM Avg
6.75%
3Y Avg
3.64%
5Y Avg
3.64%
Market Cap
$241.48M
EBITDA Yield
N/A
TTM Avg
1.55%
3Y Avg
0.84%
5Y Avg
1.10%
Market Cap
$234.98M
EBITDA Yield
5.39%
TTM Avg
11.46%
3Y Avg
13.23%
5Y Avg
11.81%
Market Cap
$234.90M
EBITDA Yield
N/A
TTM Avg
22.77%
3Y Avg
22.51%
5Y Avg
19.57%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum-Si incorporated (QSI) | $238.38M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $238.57M | 7.78% | 5.41% | 5.10% | 3.84% |
| Century Therapeutics, Inc. (IPSC)vs › | $237.21M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $236.60M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.17M | N/A | 6.75% | 3.64% | 3.64% |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $241.48M | N/A | 1.55% | 0.84% | 1.10% |
| Q32 Bio Inc. (QTTB)vs › | $241.68M | 15.57% | 32.49% | 32.49% | 32.49% |
| Utah Medical Products, Inc. (UTMD)vs › | $234.98M | 5.39% | 11.46% | 13.23% | 11.81% |
| SIGA Technologies, Inc. (SIGA)vs › | $234.90M | N/A | 22.77% | 22.51% | 19.57% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.12M | N/A | 3.52% | 3.58% | 4.02% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
